Hepalink

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
（深圳市海普瑞藥業集團股份有限公司）
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

PROPOSED INCREASE TO THE LIMIT FOR PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND CASH FLOW MANAGEMENT USING INTERNAL FUNDS AND PROPOSED ADJUSTMENT TO THE CREDIT LINE AND GUARANTEE LIMIT

Reference is made to (i) the announcements of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "**Company**") in relation to the purchase of wealth management products and cash flow management using internal funds published on the websites of the Shenzhen Stock Exchange and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on March 31, 2026 and March 30, 2026, respectively; (ii) the announcements of the Company in relation to the application for credit line and providing guarantee to the banks for 2026 published on the websites of the Shenzhen Stock Exchange and the Stock Exchange on March 31, 2026 and March 30, 2026, respectively; and (iii) the circular of the Company dated April 29, 2026 (the "**AGM Circular**"), in respect of, among other things, the purchase of wealth management products and cash flow management using internal funds and the application for credit line and providing guarantee to the banks for 2026, each of which was approved as a special resolution at the 2025 annual general meeting (the "**AGM**") of the Company held on May 22, 2026.

Proposed Increase to the Limit for Purchase of Wealth Management Products and Cash Flow Management Using Internal Funds

The Company and its subsidiaries were authorized to use self-owned funds of no more than RMB2,500 million (or equivalent foreign currency) for the purchase of wealth management products, on a revolving basis, for a period of 12 months from the date of the approval of the shareholders of the Company (the "**Shareholders**") at the AGM.

In order to improve the efficiency of utilization of short-term idle internal funds of the Company, reasonably utilize idle funds and create greater returns for the Company and the Shareholders, and on the basis of ensuring that the normal operations of the Company and its subsidiaries are not affected and that risks are effectively controlled, the board of directors of the Company (the "**Board**") proposes to increase the limit for the purchase of wealth management products and cash flow management using internal funds from RMB2,500 million (or equivalent foreign currency) to RMB3,500 million (or equivalent foreign currency) (the "**Proposed Wealth Management Products Limit Increase**"), for the period from the date of Shareholders' approval until the date of the 2026 annual general meeting of the Company. For further details regarding the Proposed Wealth Management Products Limit Increase, please refer to the announcement of the Company dated August 28, 2026 published on the websites of the Shenzhen Stock Exchange.

Proposed Adjustment to the Credit Line and Guarantee Limit

In order to further satisfy the funding needs of the business development of the Company and its wholly-owned subsidiaries and to facilitate the smooth operation of financing activities of the Company and its subsidiaries, the Board proposes to adjust the credit line and guarantee limit originally approved at the AGM. Following the proposed adjustment, the total credit line of the Company and its wholly-owned subsidiaries will remain at RMB18,540 million (with internal reallocation among the Company and its wholly-owned subsidiaries), and the total guarantee limit will be reduced from RMB10,090 million to RMB7,500 million (the "**Proposed Credit Line and Guarantee Adjustment**"). The Proposed Credit Line and Guarantee Adjustment shall be effective from the date of Shareholders' approval until the date of the 2026 annual general meeting of the Company. For further details regarding the Proposed Credit Line and Guarantee Adjustment, please refer to the announcement of the Company dated August 28, 2026 published on the websites of the Shenzhen Stock Exchange.

The proposals in connection with the Proposed Wealth Management Products Limit Increase and the Proposed Credit Line and Guarantee Adjustment were approved at the meeting of the Board held on August 28, 2026 and are subject to the approval of the Shareholders by way of an ordinary resolution and a special resolution, respectively, at an extraordinary general meeting. A circular containing further details of the Proposed Wealth Management Products Limit Increase and the Proposed Credit Line and Guarantee Adjustment, together with a notice convening the extraordinary general meeting, will be dispatched to the shareholders of the Company in due course.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
August 28, 2026

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Wang Jianyi; and the independent non-executive directors of the Company are Mr. Huang Peng, Mr. Yi Ming and Mr. Pu Hong.